| HÁJEK, Roman, Lenka ZAHRADOVÁ, Evžen GREGORA, Miroslava SCHÜTZOVÁ, Vladimír KOZA, Petr PAVLÍČEK, Luděk POUR, Marta KREJČÍ, Viera SANDECKÁ, Andrea KŘIVANOVÁ, Mohamed Abdo Saleh AL-SAHMANI, Dana KRÁLOVÁ a Zdeněk ADAM. The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance. In Fiftieth ASH Annual Meeting. 2008. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{817050,
author = {Hájek, Roman and Zahradová, Lenka and Gregora, Evžen and Schützová, Miroslava and Koza, Vladimír and Pavlíček, Petr and Pour, Luděk and Krejčí, Marta and Sandecká, Viera and Křivanová, Andrea and AlandSahmani, Mohamed Abdo Saleh and Králová, Dana and Adam, Zdeněk},
booktitle = {Fiftieth ASH Annual Meeting},
keywords = {multiple myeloma; bortezomib; treatment regimens},
title = {The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance.},
year = {2008}
}
TY - CONF
ID - 817050
AU - Hájek, Roman - Zahradová, Lenka - Gregora, Evžen - Schützová, Miroslava - Koza, Vladimír - Pavlíček, Petr - Pour, Luděk - Krejčí, Marta - Sandecká, Viera - Křivanová, Andrea - Al-Sahmani, Mohamed Abdo Saleh - Králová, Dana - Adam, Zdeněk
PY - 2008
TI - The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance.
KW - multiple myeloma
KW - bortezomib
KW - treatment regimens
N2 - In this trial, we have evaluated the potential of combinative regimen CVD (Cyclophosphamide, Bortezomib (Velcade), Dexamethasone) reduced intensity (CVD senior; 50% reduction) in elderly pts and/or pts with poor status performance with relapsed MM. The results were compared with CVD junior regimen outcome used at the same time in pts aged < 65 years and good status performance. The reduced CVD senior regimen is tolerated better than CVD junior. Duration of treatment and number of cycles was similar in both regimens. There was no difference in overall response but the higher total dose of bortezomib achieved by pts in each group resulted in a better response in both groups. The reduced intensity CVD regimen seems to be a good option for elderly pts with poor status performance with well balanced efficacy/toxicity ratio.
ER -
HÁJEK, Roman, Lenka ZAHRADOVÁ, Evžen GREGORA, Miroslava SCHÜTZOVÁ, Vladimír KOZA, Petr PAVLÍČEK, Luděk POUR, Marta KREJČÍ, Viera SANDECKÁ, Andrea KŘIVANOVÁ, Mohamed Abdo Saleh AL-SAHMANI, Dana KRÁLOVÁ a Zdeněk ADAM. The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance. In \textit{Fiftieth ASH Annual Meeting}. 2008.
|
